
Sign up to save your podcasts
Or


Special guest Luke Laffin, MD, FACC, the Co-Director, Center for Blood Pressure Disorders with the Department of Cardiovascular Medicine at the Cleveland Clinic joins us to talkabout first-line meds for hypertension.
Listen in as they discuss nuances regarding selection of a first-line medication for the treatment of hypertension.
You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board:
For the purposes of disclosure, Dr. Luke Laffin reports relevant financial relationships with CRISPR Therapeutics [hyperlipidemia], Eli Lilly [obesity], Medtronic [hypertension] (honorarium); Arrowhead [hyperlipidemia], AstraZeneca [hyperlipidemia], Mineralys Therapeutics [hypertension] (grants/research support).
The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.
TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist’s Letter or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.
Claim Credit
The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter and Prescriber Insights:
Send us a text
Email us: [email protected].
The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.
Learn more about our product offerings at trchealthcare.com.
By TRC Healthcare4.8
3636 ratings
Special guest Luke Laffin, MD, FACC, the Co-Director, Center for Blood Pressure Disorders with the Department of Cardiovascular Medicine at the Cleveland Clinic joins us to talkabout first-line meds for hypertension.
Listen in as they discuss nuances regarding selection of a first-line medication for the treatment of hypertension.
You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board:
For the purposes of disclosure, Dr. Luke Laffin reports relevant financial relationships with CRISPR Therapeutics [hyperlipidemia], Eli Lilly [obesity], Medtronic [hypertension] (honorarium); Arrowhead [hyperlipidemia], AstraZeneca [hyperlipidemia], Mineralys Therapeutics [hypertension] (grants/research support).
The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.
TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist’s Letter or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.
Claim Credit
The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter and Prescriber Insights:
Send us a text
Email us: [email protected].
The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.
Learn more about our product offerings at trchealthcare.com.

701 Listeners

500 Listeners

101 Listeners

289 Listeners

259 Listeners

3,339 Listeners

1,149 Listeners

718 Listeners

190 Listeners

514 Listeners

432 Listeners

372 Listeners

138 Listeners

3 Listeners

6 Listeners